ClinicalTrials.gg
CompletedNCT04652726ORION-16Updated Jan 13, 2026Results posted

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

A Phase 3 interventional study of Inclisiran and Placebo in Familial Hypercholesterolemia - Heterozygous, sponsored by Novartis Pharmaceuticals. Completed at 59 sites in 26 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Hyperlipoproteinemia Type II by Novartis — 4 open to participants now, 4 under way, 3 of them phase 3. Hyperlipoproteinemia Type II · Novartis.

Started
2021
the only one that year
Phase 3
5 of 11
3 open now
Registered
5th of 11
by date

Among the 11 studies in Hyperlipoproteinemia Type II by Novartis, this one is the only one that started in 2021, is one of 5 in phase 3, and was the 5th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

4 of the 11 studies in Hyperlipoproteinemia Type II by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Hyperlipoproteinemia Type II by Novartis, or all of them as a file.
02

Study summary

This was a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C).

Read the detailed description

This was a two-part (1 year double-blind inclisiran versus placebo / 1 year open-label inclisiran) multicenter study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C) on stable standard of care background lipid-lowering therapy. The primary objective was to demonstrate superiority of inclisiran compared to placebo in reducing LDL-C (percent change) at Day 330.

03

Conditions studied

  • Familial Hypercholesterolemia - Heterozygous

Keywords

  • Heterozygous familial hypercholesterolemia (HeFH)
  • LDL-cholesterol (LDL-C)
  • adolescents
  • pediatric
  • small interfering ribonucleic acid (siRNA)
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Heterozygous Familial Hypercholesterolemia (HeFH) diagnosed either by genetic testing or on phenotypic criteria
  • Fasting LDL-C >130 mg/dL (3.4 mmol/L) at screening
  • Fasting triglycerides \<400 mg/dL (4.5 mmol/L) at screening
  • On maximally tolerated dose of statin (investigator's discretion) with or without other lipid-lowering therapy; stable for ≥ 30 days before screening

Exclusion criteria

Exclusion Criteria:

  • Homozygous familial hypercholesterolemia (HoFH)
  • Active liver disease
  • Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome
  • Previous treatment with monoclonal antibodies directed towards PCSK9 (within 90 days of screening)
  • Recent and/or planned use of other medicinal products or devices
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
141 participants (actual)

Study arms

  • Experimental
    Inclisiran

    Year 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)

    Drug: Inclisiran

  • Placebo comparator
    Placebo

    Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)

    Drug: Placebo

Interventions

  • Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection

    Also known as: KJX839

  • DrugPlacebo

    Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)

    Also known as: Saline solution

06

What researchers measure

Primary outcomes

  1. Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1)

    Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 (Year 1)

    Time frame: Baseline and Day 330

Secondary outcomes

  1. Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1)

    Time-adjusted percent change in LDL-C (after Day 90 and up to Day 330), calculated as the average of percent changes from baseline to Days 150, 270 and 330

    Time frame: Baseline, after Day 90 up to Day 330

  2. Absolute Change in LDL-C From Baseline to up Day 330 (Part 1/Year 1)

    Absolute change in LDL-C from baseline to Day 330.

    Time frame: Baseline and Day 330

  3. Percent Change in Apo B From Baseline up to Day 330 (Part 1/Year 1)

    Percentage change in apolipoprotein B (Apo B) from baseline to Day 330.

    Time frame: Baseline and Day 330

  4. Percent Change in Lp(a) From Baseline up to Day 330 (Part 1/Year 1)

    Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to Day 330.

    Time frame: Baseline and Day 330

  5. Percent Change in Non-HDL-C From Baseline up to Day 330 (Part 1/Year 1)

    Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to Day 330.

    Time frame: Baseline and Day 330

  6. Percent Change in Total Cholesterol From Baseline up to Day 330 (Part 1/Year 1)

    Percentage change in total cholesterol from baseline to Day 330.

    Time frame: Baseline and Day 330

  7. Percent Change in LDL-C From Baseline up to Day 720

    Percentage change in LDL-C from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  8. Absolute Change in LDL-C From Baseline up to Day 720

    Absolute change in LDL-C from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  9. Percent Change in Apo B From Baseline up to Day 720

    Percentage change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  10. Absolute Change in Apo B From Baseline up to Day 720

    Absolute change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  11. Percent Change in Lp(a) From Baseline up to Day 720

    Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  12. Absolute Change in Lp(a) From Baseline up to Day 720

    Absolute change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  13. Percent Change in Non-HDL-C From Baseline up to Day 720

    Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  14. Absolute Change in Non-HDL-C From Baseline up to Day 720

    Absolute change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  15. Percent Change in Total Cholesterol From Baseline up to Day 720

    Percentage change in total cholesterol from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  16. Absolute Change in Total Cholesterol From Baseline up to Day 720

    Absolute change in total cholesterol from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  17. Percent Change in Triglycerides From Baseline up to Day 720

    Percentage change in triglycerides from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  18. Absolute Change in Triglycerides From Baseline up to Day 720

    Absolute change in triglycerides from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  19. Percent Change in HDL-C From Baseline up to Day 720

    Percentage change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  20. Absolute Change in HDL-C From Baseline up to Day 720

    Absolute change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  21. Percent Change in VLDL-C From Baseline up to Day 720

    Percentage change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  22. Absolut Change in VLDL-C From Baseline up to Day 720

    Absolute change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  23. Percent Change in Apo A1 From Baseline up to Day 720

    Percentage change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  24. Absolute Change in Apo A1 From Baseline up to Day 720

    Absolute change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  25. Percent Change in PCSK9 From Baseline up to Day 720

    Percentage change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  26. Absolut Change in PCSK9 From Baseline up to Day 720

    Absolute change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

07

Results

Posted Jun 10, 2025

Participant flow

141 participants were randomized in 26 countries and 51 study centers:Argentina (1), Brazil (3), Canada (1), Czech Republic (2), France (3), Germany (2), Greece (1), Hungary (1), Israel (2), Italy (4), Jordan (1), Lebanon (1), Malaysia (1), Netherlands (2), Norway (1), Poland (2), Russian Federation (2), Slovakia (1), Slovenia (1), South Africa (3), Spain (4), Switzerland (1), Taiwan (1), Turkey (4), United Kingdom (1), and United States of America (5).

Part 1 (Double-blind Period)
Participant flow — Part 1 (Double-blind Period)
MilestonePart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Started93480
Completed91480
Not completed200
Withdrew: Physician decision100
Withdrew: Participant/guardian decision100
Part 2 (Open-label Period)
Participant flow — Part 2 (Open-label Period)
MilestonePart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Started00139
Completed00139
Not completed000

Outcome measures

PrimaryPercentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1)

Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 (Year 1)

Time frame:
Baseline and Day 330
Reported as:
Least squares mean · percent change in LDL-C
Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1)
percent change in LDL-CPart 1- InclisiranPart 1 - Placebo
Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1)-27.14 (-32.04 to -22.24)1.40 (-3.97 to 6.78)
Statistical analysis
  • Part 1- Inclisiran vs Part 1 - Placebo · ANCOVA · p = <.0001 · Ls mean: -28.54 · 95% CI -35.81 to -21.27
SecondaryTime-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1)

Time-adjusted percent change in LDL-C (after Day 90 and up to Day 330), calculated as the average of percent changes from baseline to Days 150, 270 and 330

Time frame:
Baseline, after Day 90 up to Day 330
Reported as:
Least squares mean · Time-adjusted percent change in LDL-C
Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1)
Time-adjusted percent change in LDL-CPart 1- InclisiranPart 1 - Placebo
Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1)-26.04 (-30.11 to -21.98)3.26 (-2.37 to 8.89)
Statistical analysis
  • Part 1- Inclisiran vs Part 1 - Placebo · MMRM · p = <.0001 · Ls mean: -29.30 · 95% CI -36.24 to -22.36
SecondaryAbsolute Change in LDL-C From Baseline to up Day 330 (Part 1/Year 1)

Absolute change in LDL-C from baseline to Day 330.

Time frame:
Baseline and Day 330
Reported as:
Least squares mean · mg/dL
Absolute Change in LDL-C From Baseline to up Day 330 (Part 1/Year 1)
mg/dLPart 1- InclisiranPart 1 - Placebo
Absolute Change in LDL-C From Baseline to up Day 330 (Part 1/Year 1)-50.54 (-59.22 to -41.86)-0.55 (-10.48 to 9.38)
Statistical analysis
  • Part 1- Inclisiran vs Part 1 - Placebo · ANCOVA · p = <.0001 · Ls mean: -49.99 · 95% CI -63.18 to -36.81
SecondaryPercent Change in Apo B From Baseline up to Day 330 (Part 1/Year 1)

Percentage change in apolipoprotein B (Apo B) from baseline to Day 330.

Time frame:
Baseline and Day 330
Reported as:
Least squares mean · Percent change in Apo B
Percent Change in Apo B From Baseline up to Day 330 (Part 1/Year 1)
Percent change in Apo BPart 1- InclisiranPart 1 - Placebo
Percent Change in Apo B From Baseline up to Day 330 (Part 1/Year 1)-21.46 (-25.59 to -17.33)4.24 (-0.07 to 8.56)
Statistical analysis
  • Part 1- Inclisiran vs Part 1 - Placebo · ANCOVA · p = <.0001 · Ls mean: -25.70 · 95% CI -31.68 to -19.73
SecondaryPercent Change in Lp(a) From Baseline up to Day 330 (Part 1/Year 1)

Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to Day 330.

Time frame:
Baseline and Day 330
Reported as:
Least squares mean · Percent change in Lp(a)
Percent Change in Lp(a) From Baseline up to Day 330 (Part 1/Year 1)
Percent change in Lp(a)Part 1- InclisiranPart 1 - Placebo
Percent Change in Lp(a) From Baseline up to Day 330 (Part 1/Year 1)-5.04 (-14.21 to 4.13)1.14 (-5.48 to 7.77)
Statistical analysis
  • Part 1- Inclisiran vs Part 1 - Placebo · ANCOVA · p = 0.1419 · Ls mean: -6.18 · 95% CI -17.48 to 5.12
SecondaryPercent Change in Non-HDL-C From Baseline up to Day 330 (Part 1/Year 1)

Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to Day 330.

Time frame:
Baseline and Day 330
Reported as:
Least squares mean · Percent change in non-HDL-C
Percent Change in Non-HDL-C From Baseline up to Day 330 (Part 1/Year 1)
Percent change in non-HDL-CPart 1- InclisiranPart 1 - Placebo
Percent Change in Non-HDL-C From Baseline up to Day 330 (Part 1/Year 1)-25.04 (-29.68 to -20.41)1.76 (-3.25 to 6.77)
Statistical analysis
  • Part 1- Inclisiran vs Part 1 - Placebo · ANCOVA · p = <.0001 · Ls mean: -26.80 · 95% CI -33.63 to -19.97
SecondaryPercent Change in Total Cholesterol From Baseline up to Day 330 (Part 1/Year 1)

Percentage change in total cholesterol from baseline to Day 330.

Time frame:
Baseline and Day 330
Reported as:
Least squares mean · Percent change in total cholesterol
Percent Change in Total Cholesterol From Baseline up to Day 330 (Part 1/Year 1)
Percent change in total cholesterolPart 1- InclisiranPart 1 - Placebo
Percent Change in Total Cholesterol From Baseline up to Day 330 (Part 1/Year 1)-18.72 (-22.48 to -14.96)0.48 (-3.46 to 4.42)
Statistical analysis
  • Part 1- Inclisiran vs Part 1 - Placebo · ANCOVA · p = <.0001 · Ls mean: -19.20 · 95% CI -24.65 to -13.75
SecondaryPercent Change in LDL-C From Baseline up to Day 720

Percentage change in LDL-C from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in LDL-C
Percent Change in LDL-C From Baseline up to Day 720
Percent change in LDL-CPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 90-23.9 ± 22.14-0.1 ± 20.16—
DAY 150-32.5 ± 21.476.4 ± 28.83—
DAY 270-19.0 ± 28.312.1 ± 22.44—
DAY 330-27.8 ± 22.951.5 ± 20.59—
DAY 360-26.1 ± 22.711.5 ± 30.56—
DAY 450——-24.5 ± 26.45
DAY 510——-32.5 ± 22.80
DAY 630——-26.5 ± 24.33
Day 720 (study completion)——-33.7 ± 23.98
SecondaryAbsolute Change in LDL-C From Baseline up to Day 720

Absolute change in LDL-C from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in LDL-C From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 90-45.4 ± 45.26-3.0 ± 35.02—
DAY 150-61.0 ± 45.846.6 ± 46.22—
DAY 270-38.4 ± 55.771.0 ± 36.92—
DAY 330-51.9 ± 45.47-0.3 ± 38.04—
DAY 360-49.0 ± 44.49-2.9 ± 51.74—
DAY 450——-46.3 ± 52.51
DAY 510——-60.8 ± 48.88
DAY 630——-50.9 ± 50.30
Day 720 (study completion)——-64.1 ± 53.91
SecondaryPercent Change in Apo B From Baseline up to Day 720

Percentage change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in Apo B
Percent Change in Apo B From Baseline up to Day 720
Percent change in Apo BPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 150-25.1 ± 18.182.2 ± 20.77—
DAY 330-21.9 ± 19.513.9 ± 18.13—
DAY 360-19.3 ± 21.361.7 ± 22.70—
DAY 510——-24.5 ± 21.77
Day 720 (study completion)——-25.7 ± 21.71
SecondaryAbsolute Change in Apo B From Baseline up to Day 720

Absolute change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in Apo B From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 150-33.3 ± 28.200.0 ± 27.38—
DAY 330-29.2 ± 28.042.9 ± 23.47—
DAY 360-26.1 ± 29.59-0.6 ± 28.72—
DAY 510——-33.5 ± 32.13
Day 720 (study completion)——-35.4 ± 33.83
SecondaryPercent Change in Lp(a) From Baseline up to Day 720

Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in Lp(a)
Percent Change in Lp(a) From Baseline up to Day 720
Percent change in Lp(a)Part 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 150-13.4 ± 22.605.4 ± 23.96—
DAY 330-7.2 ± 30.801.1 ± 24.25—
DAY 360-9.3 ± 28.443.6 ± 23.27—
DAY 510——-13.3 ± 28.81
Day 720 (study completion)——-4.2 ± 163.74
SecondaryAbsolute Change in Lp(a) From Baseline up to Day 720

Absolute change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · nmol/L
Absolute Change in Lp(a) From Baseline up to Day 720
nmol/LPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 150-12.5 ± 34.733.2 ± 20.67—
DAY 330-9.5 ± 33.815.3 ± 21.55—
DAY 360-10.2 ± 31.164.4 ± 22.99—
DAY 510——-10.1 ± 34.98
Day 720 (study completion)——-9.0 ± 50.08
SecondaryPercent Change in Non-HDL-C From Baseline up to Day 720

Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in non-HDL-C
Percent Change in Non-HDL-C From Baseline up to Day 720
Percent change in non-HDL-CPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 150-29.0 ± 20.155.1 ± 24.85—
DAY 330-25.7 ± 21.691.8 ± 19.43—
DAY 360-24.0 ± 21.741.2 ± 27.43—
DAY 510——-29.9 ± 21.60
Day 720 (study completion)——-31.0 ± 23.04
SecondaryAbsolute Change in Non-HDL-C From Baseline up to Day 720

Absolute change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in Non-HDL-C From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 150-60.2 ± 47.415.7 ± 47.61—
DAY 330-52.6 ± 46.930.5 ± 39.20—
DAY 360-49.7 ± 46.30-3.0 ± 52.75—
DAY 510——-62.0 ± 51.09
Day 720 (study completion)——-65.1 ± 56.16
SecondaryPercent Change in Total Cholesterol From Baseline up to Day 720

Percentage change in total cholesterol from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in total cholesterol
Percent Change in Total Cholesterol From Baseline up to Day 720
Percent change in total cholesterolPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 150-22.6 ± 15.774.4 ± 20.49—
DAY 330-19.2 ± 17.770.6 ± 15.46—
DAY 360-18.5 ± 17.180.6 ± 21.81—
DAY 510——-23.0 ± 17.50
Day 720 (study completion)——-23.7 ± 18.29
SecondaryAbsolute Change in Total Cholesterol From Baseline up to Day 720

Absolute change in total cholesterol from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in Total Cholesterol From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 150-59.0 ± 47.796.6 ± 48.08—
DAY 330-49.4 ± 47.77-0.9 ± 38.48—
DAY 360-48.2 ± 47.06-3.1 ± 52.66—
DAY 510——-59.6 ± 51.06
Day 720 (study completion)——-62.3 ± 55.05
SecondaryPercent Change in Triglycerides From Baseline up to Day 720

Percentage change in triglycerides from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in triglycerides
Percent Change in Triglycerides From Baseline up to Day 720
Percent change in triglyceridesPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 15016.2 ± 78.182.8 ± 37.44—
DAY 3301.8 ± 38.399.7 ± 43.04—
DAY 3601.7 ± 40.033.8 ± 35.76—
DAY 510——3.4 ± 43.08
Day 720 (study completion)——1.9 ± 41.84
SecondaryAbsolute Change in Triglycerides From Baseline up to Day 720

Absolute change in triglycerides from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in Triglycerides From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 1506.9 ± 64.67-4.8 ± 31.53—
DAY 330-2.9 ± 35.013.5 ± 35.55—
DAY 360-3.1 ± 38.13-1.7 ± 28.47—
DAY 510——-4.2 ± 34.70
Day 720 (study completion)——-4.8 ± 36.21
SecondaryPercent Change in HDL-C From Baseline up to Day 720

Percentage change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in HDL-C
Percent Change in HDL-C From Baseline up to Day 720
Percent change in HDL-CPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 1503.6 ± 18.883.6 ± 16.49—
DAY 3307.4 ± 19.15-1.9 ± 16.15—
DAY 3604.4 ± 19.540.9 ± 12.39—
DAY 510——6.6 ± 19.84
Day 720 (study completion)——7.4 ± 20.40
SecondaryAbsolute Change in HDL-C From Baseline up to Day 720

Absolute change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in HDL-C From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 1501.2 ± 10.230.9 ± 8.07—
DAY 3303.2 ± 9.57-1.4 ± 7.77—
DAY 3601.5 ± 9.59-0.1 ± 6.23—
DAY 510——2.4 ± 9.32
Day 720 (study completion)——2.8 ± 9.75
SecondaryPercent Change in VLDL-C From Baseline up to Day 720

Percentage change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in VLDL-C
Percent Change in VLDL-C From Baseline up to Day 720
Percent change in VLDL-CPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 15011.8 ± 60.043.3 ± 38.25—
DAY 3300.6 ± 39.0010.0 ± 42.29—
DAY 3601.0 ± 40.154.7 ± 35.65—
DAY 510——1.4 ± 41.13
Day 720 (study completion)——1.9 ± 42.20
SecondaryAbsolut Change in VLDL-C From Baseline up to Day 720

Absolute change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolut Change in VLDL-C From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 1500.7 ± 10.02-0.9 ± 6.37—
DAY 330-0.7 ± 7.040.8 ± 7.07—
DAY 360-0.7 ± 7.63-0.2 ± 5.66—
DAY 510——-1.2 ± 6.90
Day 720 (study completion)——-1.0 ± 7.40
SecondaryPercent Change in Apo A1 From Baseline up to Day 720

Percentage change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in Apo A1
Percent Change in Apo A1 From Baseline up to Day 720
Percent change in Apo A1Part 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 1503.7 ± 15.400.4 ± 13.22—
DAY 3305.2 ± 14.49-1.5 ± 10.58—
DAY 3603.0 ± 15.12-1.5 ± 9.98—
DAY 510——6.3 ± 16.19
Day 720 (study completion)——4.9 ± 15.56
SecondaryAbsolute Change in Apo A1 From Baseline up to Day 720

Absolute change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in Apo A1 From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 1503.3 ± 21.760.0 ± 17.72—
DAY 3306.1 ± 21.16-2.8 ± 14.24—
DAY 3602.7 ± 21.87-2.6 ± 13.89—
DAY 510——7.5 ± 22.24
Day 720 (study completion)——5.4 ± 21.61
SecondaryPercent Change in PCSK9 From Baseline up to Day 720

Percentage change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in PCSK9
Percent Change in PCSK9 From Baseline up to Day 720
Percent change in PCSK9Part 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 90-67.8 ± 15.1711.6 ± 46.61—
DAY 150-72.3 ± 11.373.8 ± 36.95—
DAY 330-72.9 ± 12.124.8 ± 34.50—
DAY 360-72.0 ± 10.4711.7 ± 57.77—
DAY 510——-74.3 ± 10.46
Day 720 (study completion)——-71.6 ± 13.42
SecondaryAbsolut Change in PCSK9 From Baseline up to Day 720

Absolute change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · ng/mL
Absolut Change in PCSK9 From Baseline up to Day 720
ng/mLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
DAY 90-259.6 ± 121.52.1 ± 223.16—
DAY 150-274.8 ± 116.2-27.7 ± 210.44—
DAY 330-278.2 ± 119.8-23.9 ± 210.85—
DAY 360-275.4 ± 117.2-9.1 ± 245.36—
DAY 510——-288.1 ± 156.9
Day 720 (study completion)——-279.5 ± 159.2

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 90 days post treatment or 30 days after last study visit, whichever was longer, up to a maximum duration of approximately 2 years.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 - Inclisiran0/93 (0%)3/93 (3.2%)57/93 (61.3%)
Part 1 - Placebo0/48 (0%)1/48 (2.1%)29/48 (60.4%)
Part 2 - Inclisiran (Total)0/139 (0%)6/139 (4.3%)52/139 (37.4%)
Most frequent serious events
Most frequent serious events
EventPart 1 - InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Supraventricular tachycardiaCardiac disorders0/931/480/139
Anaphylactic reactionImmune system disorders1/930/481/139
Dengue feverInfections and infestations1/930/480/139
Status migrainosusNervous system disorders1/930/480/139
ConcussionInjury, poisoning and procedural complications0/930/481/139
Blood creatine phosphokinase increasedInvestigations0/930/481/139
SyncopeNervous system disorders0/930/481/139
AnxietyPsychiatric disorders0/930/481/139
Varicose veinVascular disorders0/930/481/139
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPart 1 - InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
COVID-19Infections and infestations17/9312/487/139
NasopharyngitisInfections and infestations13/939/4814/139
HeadacheNervous system disorders12/933/486/139
InfluenzaInfections and infestations10/936/4811/139
Injection site reactionGeneral disorders8/931/485/139
Upper respiratory tract infectionInfections and infestations6/932/484/139
Influenza like illnessGeneral disorders4/933/482/139
VomitingGastrointestinal disorders5/931/480/139
SyncopeNervous system disorders5/930/481/139
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/932/486/139

Baseline characteristics

Baseline Characteristics are based on all randomized participants

Age, Categorical
Age, Categorical(Participants)Part 1- InclisiranPart 1 - PlaceboTotal
<=18 years9348141
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)Part 1- InclisiranPart 1 - PlaceboTotal
Mean15.2 ± 2.0214.9 ± 1.8015.1 ± 1.94
Sex: Female, Male
Sex: Female, Male(Participants)Part 1- InclisiranPart 1 - PlaceboTotal
Female512475
Male422466
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1- InclisiranPart 1 - PlaceboTotal
Asian404
Black or African American505
Other404
White8048128
08

Study locations

59 sites
  • Tucson Medical Center
    Tucson, Arizona 85712, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Wake Forest U of Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • Childrens Hospital Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Primary Children's Medical Center
    Salt Lake City, Utah 84113, United States
  • Novartis Investigative Site
    Formosa, Formosa Province P3600, Argentina
  • Unidade de pesquisa clinica - Hospital Universitario Walter Cantidio
    Fortaleza, Ceará 60430275, Brazil
  • Nucleo de Pesquisa Clinica do Rio Grande do Sul
    Porto Alegre, Rio Grande do Sul 90430-001, Brazil
  • Setor de Lípides, Aterosclerose e Biologia
    São Paulo, São Paulo 04023-900, Brazil
  • Heart Institute (InCOr) HCMFUSP
    São Paulo, São Paulo 05403 000, Brazil
  • Novartis Investigative Site
    Québec, Quebec G1V 4W2, Canada
  • Novartis Investigative Site
    Prague, 12808, Czechia
  • Novartis Investigative Site
    Prague, 150 06, Czechia
  • Novartis Investigative Site
    Besançon, 25030, France
  • Novartis Investigative Site
    Bron, 69677, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Universitaetsmedizin Mannheim
    Mannheim, Baden-Wurttemberg 68305, Germany
  • KKIM UK Frankfurt/Main
    Frankfurt, 60590, Germany
  • Universitaetsklinikum Freiburg
    Freiburg im Breisgau, 79106, Germany
  • University General Hospital of Ioannina
    Ioannina, GR 455 00, Greece
  • Hippokrateion General Hospital of Athens Greece
    Athens, 115 27, Greece
  • Metropolitan Hospital
    Athens, 18547, Greece
  • Novartis Investigative Site
    Pécs, 7623, Hungary
  • Lipid Research
    Jerusalem, 9112001, Israel
  • Lipids Center Sheba Medical Center, Israel
    Ramat Gan, 52621, Israel
  • Novartis Investigative Site
    Milan, MI 20162, Italy
  • Novartis Investigative Site
    Modena, MO 41124, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Roma, RM 00165, Italy
  • Novartis Investigative Site
    Irbid, 22110, Jordan
  • Hotel Dieu de France Hospital
    El Achrafiyé, 166830, Lebanon
  • UiTM Sungai Buloh
    Sungai Buloh, Selangor 47000, Malaysia
  • Novartis Investigative Site
    Rotterdam, South Holland 3015 GD, Netherlands
  • Novartis Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • Novartis Investigative Site
    Oslo, 0514, Norway
  • Novartis Investigative Site
    Gdansk, 80 952, Poland
  • Novartis Investigative Site
    Lodz, 93-338, Poland
  • Institute of the complex problems of cardiovascular disease
    Kemerovo, 650002, Russia
  • Novartis Investigative Site
    Moscow, 127412, Russia
  • Institute of Internal Prev. Med.
    Novosibirsk, 630090, Russia
  • Novartis Investigative Site
    Poprad, 058 01, Slovakia
  • University Medical Centre Ljubljana, Div. of Pediatric Dept. of Endocrinology, Diabetes and Metabolic Diseases
    Ljubljana, 1000, Slovenia
  • Novartis Investigative Site
    Bloemfontein, Free State 9301, South Africa
  • Novartis Investigative Site
    Somerset West, Western Cape 7130, South Africa
  • Novartis Investigative Site
    Cape Town, 7925, South Africa
  • Hospital Reina Sofia
    Córdoba, Andalusia 14004, Spain
  • Hospital Virgen de la Vcitoria
    Málaga, Andalusia 29010, Spain
  • Novartis Investigative Site
    Pamplona, Navarre 31008, Spain
  • Hospital Central de Asturias
    Oviedo, Principality of Asturias 33011, Spain
  • Hospital Abente y Lago
    A Coruña, 15001, Spain
  • Novartis Investigative Site
    Geneva, 1211, Switzerland
  • Far Eastern Memorial Hospital
    New Taipei City, 22060, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Novartis Investigative Site
    Istanbul, TUR 34098, Turkey (Türkiye)
  • Novartis Investigative Site
    Adana, 01330, Turkey (Türkiye)
  • Gazi University Medical Faculty
    Ankara, 06500, Turkey (Türkiye)
  • Novartis Investigative Site
    Izmir, 35100, Turkey (Türkiye)
  • Novartis Investigative Site
    Middlesex, UB9 6JH, United Kingdom
09

References and documents

Publications

  • Wiegman A, Peterson AL, Bruckert E, Defesche JC, Schweizer A, Bergeron J, Chueca MJ, Roeters van Lennep JE, Santos RD, Schwab KO, Lesogor A, Zhang S, Hegele RA. Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial. Lancet Diabetes Endocrinol. 2026 Mar;14(3):233-242. doi: 10.1016/S2213-8587(25)00351-1. Epub 2026 Jan 27. PubMed 41616799 ↗
  • Reijman MD, Schweizer A, Peterson ALH, Bruckert E, Stratz C, Defesche JC, Hegele RA, Wiegman A. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2022 Jul 20;29(9):1361-1368. doi: 10.1093/eurjpc/zwac025. PubMed 35175352 ↗
  • Warden BA, Duell PB. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053. PubMed 33990512 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Nov 2023, 33 months.

Results were first posted in Jun 2025, 1 year 7 months after primary completion. A results delay was requested in Jun 2024.

Of 29 industry-sponsored phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 33 months is above that.

Counting every sponsor, half of 33 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2020
First posted
Dec 3, 2020
StartActual
Jan 27, 2021
Primary completionActual
Nov 9, 2023
CompletionActual
Nov 27, 2024
Results delay requested
Jun 14, 2024
Results first posted
Jun 10, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04652726
Responsible party
Sponsor
First posted
Dec 3, 2020
Start date
Jan 27, 2021
Primary completion
Nov 9, 2023
Completion
Nov 27, 2024
Results posted
Jun 10, 2025
Last update
Jan 13, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion